ATORM
Adult Tissue derived Organoid based Regenerative Medicine
Organoid-based regenerative therapeutics platform
Local transplantation
with scaffolds
Patient
Establishment
of organoids
Biopsy by minimal
invasive methods
- Certificate of Advanced Technology Product
- Designation as a National Strategic Technology
Pipeline
Establishment of 4 types of organoid pipelines
Full-scale clinical trials underway for intestinal and salivary gland organoid pipelines
Full-scale clinical trials underway for intestinal and salivary gland organoid pipelines
ATORM-C
Intestinal organoid regenerative therapeutic
ATORM-S
Salivary gland organoid regenerative therapeutic
ATORM-E
Endometrium organoid regenerative therapeutic
ATORM-L
Liver organoid regenerative therapeutic
Core Technology
Development of Core Technologies for the Commercialization of Organoid-Based Regenerative Therapies, including Organoid Formulations, GMP-Grade Manufacturing, and Administration Methods
Development of organoid production technology containing high concentrations of stem cells
Our proprietary technology yields intestinal organoids with over four times the stem cell content of native human tissue, significantly enhancing regenerative potential.
Development of delivery method using endoscopy
We developed a user-friendly delivery technique using endoscopy. Therapeutics and fixation materials are injected separately, improving localization while reducing toxicity.
Consistent and optimized organoid culture
ATORM-C Overview
Tissue damage caused by inflammation and radiation leading to serious complications
ATORM-C offers fundamental treatment that induces regeneration of damaged intestinal tissue
ATORM-C offers fundamental treatment that induces regeneration of damaged intestinal tissue
Refractory intestinal ulcers that do not respond for over a year even after drug treatment
Mechanism and treatment of intractable intestinal ulcers
Inflammation
Treated with various anti-inflammatory agents
Mucosal damage
No established treatment currently availableATORM-C Introduction Video
Domestic and global clinical development plans
ATORM-C advanced regenerative medicine clinical research is expected to be commercialized in Korea hospitals in 2027
ATORM-C (Colon Organoids)
Refractory inflammatory bowel diseases (IBD)
Programs (Indications)
Domestic
(Advanced Regenerative Medicine, Chungbuk Regenerative Bio Special Zone)
Development Stage
Collaboration
- Seoul Asan Medical Center
- Bundang CHA Hospital
- Korea University Medical Center
- Dongguk University Ilsan Hospital
- Yonsei University
Programs (Indications)
Global Commercialization
(Multinational Phase 2 trial following Korean Phase 1 trial to support BLA in the USA and EU) Collaboration
- Mount Sinai NY
- UKSH (Universitätsklinikum Schleswig-Holstein)
- Mahidol University
- UKD (University Hospital Dresden ‘Carl Gustav Carus’)
ATORM-S (Salivary Organoids)
Refractory salivary gland hypofunction
Programs (Indications)
Domestic
(Advanced Regenerative Medicine, Chungbuk Regenerative Bio Special Zone) Development Stage
Collaboration
- Konkuk University Medical Center
- Samsung Medical Center
ORGANOIDSCIENCES
If you have any inquiries about ORGANOIDSCIENCES’ solutions, research collaborations, or partnership opportunities, please leave us a message.
Our team will review your inquiry and connect you with the appropriate expert.
Our team will review your inquiry and connect you with the appropriate expert.